Brixton Biosciences, Inc.
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.0Mattributed |
|---|---|
| Latest round | grant, $2.0M, 2024-01-01attributed |
| Founded | unknown |
| Headquarters | Cambridge, Massachusetts |
| Industry | unknown |
| Stage | unknown |
| Website | brixtonbio.com |
Reneurx, a nerve-selective injectable therapy for long-acting pain relief — up to six months per single treatment. Built for pain-management partners and clinical co-development. Investigational stage; differentiates on selective-nerve targeting versus broad nerve blocks.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | grant | $2.0M | undisclosed |
Detected tech stack
Cloudflare, Google Font API, Google Hosted Libraries, DoubleClick Floodlight, WordPress, PHP, MySQL, jquery 3.5.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.0M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $2.0M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | brixtonbio.com, read 2026-05-02 |
| Description | self-reported | brixtonbio.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.